ECSP088793A - Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo - Google Patents

Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo

Info

Publication number
ECSP088793A
ECSP088793A EC2008008793A ECSP088793A ECSP088793A EC SP088793 A ECSP088793 A EC SP088793A EC 2008008793 A EC2008008793 A EC 2008008793A EC SP088793 A ECSP088793 A EC SP088793A EC SP088793 A ECSP088793 A EC SP088793A
Authority
EC
Ecuador
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
EC2008008793A
Other languages
English (en)
Inventor
Klaus Schiene
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37025148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of ECSP088793A publication Critical patent/ECSP088793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la combinación que comprende componentes como (a) el compuesto (3-(3-dimetilamino-1etil-2-metil-propil)-fenol y (b) Paracetamol o derivados de él, una formulación farmacéutica y una dosis que comprende dicha combinación así como un método de tratamiento del dolor, e.g. dolor crónico o agudo caracterizado en esos componentes (a) y (b) son administrados simultáneamente o secuencialmente a un mamífero, donde el componente (a) puede ser administrado antes o después que el componente (b) y donde los componentes (a) y (b) son administrados a un mamífero por la misma o diferente vía de administración.
EC2008008793A 2006-04-28 2008-10-06 Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo ECSP088793A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06008851 2006-04-28

Publications (1)

Publication Number Publication Date
ECSP088793A true ECSP088793A (es) 2008-11-27

Family

ID=37025148

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2008008793A ECSP088793A (es) 2006-04-28 2008-10-06 Combinación Farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamo
ECIEPI2017643A ECSP17000643A (es) 2006-04-28 2017-01-05 Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECIEPI2017643A ECSP17000643A (es) 2006-04-28 2017-01-05 Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.

Country Status (25)

Country Link
EP (1) EP2012764B1 (es)
JP (2) JP5496653B2 (es)
KR (1) KR101396166B1 (es)
CN (1) CN101431990B (es)
AT (1) ATE494889T1 (es)
AU (1) AU2007247481B2 (es)
BR (1) BRPI0710682B8 (es)
CA (1) CA2650423C (es)
CY (1) CY1111369T1 (es)
DE (1) DE602007011913D1 (es)
DK (1) DK2012764T3 (es)
EC (2) ECSP088793A (es)
ES (1) ES2356093T3 (es)
HK (1) HK1127289A1 (es)
HR (1) HRP20110076T1 (es)
IL (1) IL194883A (es)
MX (1) MX2008013779A (es)
NO (2) NO341602B1 (es)
NZ (1) NZ571442A (es)
PL (1) PL2012764T3 (es)
PT (1) PT2012764E (es)
RU (1) RU2442576C2 (es)
SI (1) SI2012764T1 (es)
WO (1) WO2007128413A1 (es)
ZA (1) ZA200810124B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
KR101831616B1 (ko) 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
MX351584B (es) 2011-03-04 2017-10-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
US20120225951A1 (en) * 2011-03-04 2012-09-06 Gruenenthal Gmbh Parenteral Administration of Tapentadol
EP2680834B1 (en) 2011-03-04 2017-10-18 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
LT3273953T (lt) 2015-03-27 2019-02-25 Grünenthal GmbH Stabili kompozicija, skirta tapentadolio skyrimui parenteriniu būdu
EP3515412A1 (en) 2016-09-23 2019-07-31 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1685829B1 (de) * 2002-11-22 2008-04-09 Grünenthal GmbH Verwendung von (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexan-1,3-diol zur Behandlung von Entzündungsschmerz

Also Published As

Publication number Publication date
BRPI0710682A2 (pt) 2011-08-23
PL2012764T3 (pl) 2011-04-29
ES2356093T3 (es) 2011-04-04
HRP20110076T1 (hr) 2011-02-28
KR101396166B1 (ko) 2014-05-27
RU2442576C2 (ru) 2012-02-20
EP2012764A1 (en) 2009-01-14
JP2009535313A (ja) 2009-10-01
KR20090006219A (ko) 2009-01-14
PT2012764E (pt) 2011-02-02
JP5496653B2 (ja) 2014-05-21
AU2007247481B2 (en) 2013-02-14
MX2008013779A (es) 2008-11-14
CN101431990A (zh) 2009-05-13
AU2007247481A1 (en) 2007-11-15
CY1111369T1 (el) 2015-08-05
ZA200810124B (en) 2009-08-26
NO341602B1 (no) 2017-12-11
HK1127289A1 (en) 2009-09-25
CN101431990B (zh) 2011-08-03
DK2012764T3 (da) 2011-02-28
SI2012764T1 (sl) 2011-03-31
CA2650423A1 (en) 2007-11-15
NO20171831A1 (no) 2008-10-28
EP2012764B1 (en) 2011-01-12
BRPI0710682B1 (pt) 2020-09-24
ECSP17000643A (es) 2018-06-30
IL194883A (en) 2012-10-31
NO343505B1 (no) 2019-03-25
IL194883A0 (en) 2009-08-03
CA2650423C (en) 2014-08-12
JP2013213045A (ja) 2013-10-17
ATE494889T1 (de) 2011-01-15
NZ571442A (en) 2011-09-30
RU2008146816A (ru) 2010-06-10
BRPI0710682B8 (pt) 2021-05-25
WO2007128413A1 (en) 2007-11-15
DE602007011913D1 (de) 2011-02-24
NO20084542L (no) 2008-10-28

Similar Documents

Publication Publication Date Title
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
MX2008013828A (es) Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
WO2010025931A3 (en) Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0622054B8 (pt) composto e composição farmacêutica
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
WO2007143607A3 (en) Method of treating atrophic vaginitis
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
CR11418A (es) Trans-clomifeno para el sindrome metabolico
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
CL2009000388A1 (es) Compuestos derivados de biciclos nitrogenados; proceso de preparacion; composicion farmaceutica; y su uso para tratar el dolor cronico que surge por inflamacion o neuropatia.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
BRPI0506551A (pt) uso do metronidazol para a preparação de uma composição farmacêutica
CL2007003284A1 (es) Composicion farmaceutica que comprende una asociacion de i) ciclobenzaprina, ii) aceclofenaco y opcionalmente iii) excipientes; y su uso para el tratamiento de enfermedades musculares dolorosas.
CL2011000095A1 (es) Uso de una forma de dosificacion que comprende un descongestionante y un corticoesteroide para preparar un medicamento util para tratar o aliviar uno o mas sintomas de una condicion alergica o inflamatoria; forma de dosificacion.